Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($0.56), $0.17 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $195.99 million versus the consensus estimate of $189.81 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Tesco explores sale of Central and Eastern Europe operations, Morgan Stanley chimes in
• Ticombo Releases World Cup 2026 Final Ticket Availability Report